Mangoceuticals, Inc. (MGRX) Stock Competitors & Peer Comparison
See (MGRX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MGRX | $0.36 | -5.66% | 3.7M | -0.27 | -$1.35 | N/A |
| GEHC | $63.83 | -2.94% | 29.6B | 14.27 | $4.56 | +0.22% |
| VEEV | $175.60 | +2.47% | 28.6B | 21.15 | $8.33 | N/A |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSGU | $227.08 | -0.39% | 13.6B | 206.76 | $1.11 | N/A |
| BTSG | $69.15 | +0.24% | 13.5B | 55.63 | $1.24 | N/A |
| TEM | $57.40 | +2.24% | 10.2B | -116.62 | -$0.50 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $89.70 | +1.40% | 7.3B | 20.52 | $4.28 | N/A |
| HNGE | $83.34 | +5.53% | 6.3B | 41.71 | $1.95 | N/A |
Stock Comparison
MGRX vs GEHC Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, GEHC has a market cap of 29.6B. Regarding current trading prices, MGRX is priced at $0.36, while GEHC trades at $63.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas GEHC's P/E ratio is 14.27. In terms of profitability, MGRX's ROE is -1.21%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, MGRX is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check GEHC's competition here
MGRX vs VEEV Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, VEEV has a market cap of 28.6B. Regarding current trading prices, MGRX is priced at $0.36, while VEEV trades at $175.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas VEEV's P/E ratio is 21.15. In terms of profitability, MGRX's ROE is -1.21%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, MGRX is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check VEEV's competition here
MGRX vs GEHCV Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, MGRX is priced at $0.36, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas GEHCV's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, MGRX is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check GEHCV's competition here
MGRX vs BTSGU Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, BTSGU has a market cap of 13.6B. Regarding current trading prices, MGRX is priced at $0.36, while BTSGU trades at $227.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas BTSGU's P/E ratio is 206.76. In terms of profitability, MGRX's ROE is -1.21%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check BTSGU's competition here
MGRX vs BTSG Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, BTSG has a market cap of 13.5B. Regarding current trading prices, MGRX is priced at $0.36, while BTSG trades at $69.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas BTSG's P/E ratio is 55.63. In terms of profitability, MGRX's ROE is -1.21%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check BTSG's competition here
MGRX vs TEM Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, TEM has a market cap of 10.2B. Regarding current trading prices, MGRX is priced at $0.36, while TEM trades at $57.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas TEM's P/E ratio is -116.62. In terms of profitability, MGRX's ROE is -1.21%, compared to TEM's ROE of -0.70%. Regarding short-term risk, MGRX is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check TEM's competition here
MGRX vs SGFY Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, MGRX is priced at $0.36, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SGFY's P/E ratio is 70.91. In terms of profitability, MGRX's ROE is -1.21%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, MGRX is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SGFY's competition here
MGRX vs HQY Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, HQY has a market cap of 7.3B. Regarding current trading prices, MGRX is priced at $0.36, while HQY trades at $89.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas HQY's P/E ratio is 20.52. In terms of profitability, MGRX's ROE is -1.21%, compared to HQY's ROE of +0.11%. Regarding short-term risk, MGRX is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check HQY's competition here
MGRX vs HNGE Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, HNGE has a market cap of 6.3B. Regarding current trading prices, MGRX is priced at $0.36, while HNGE trades at $83.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas HNGE's P/E ratio is 41.71. In terms of profitability, MGRX's ROE is -1.21%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, MGRX is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check HNGE's competition here
MGRX vs RCM Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, MGRX is priced at $0.36, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas RCM's P/E ratio is -102.21. In terms of profitability, MGRX's ROE is -1.21%, compared to RCM's ROE of +0.00%. Regarding short-term risk, MGRX is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check RCM's competition here
MGRX vs TXG Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, TXG has a market cap of 4.7B. Regarding current trading prices, MGRX is priced at $0.36, while TXG trades at $37.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas TXG's P/E ratio is -218.53. In terms of profitability, MGRX's ROE is -1.21%, compared to TXG's ROE of -0.03%. Regarding short-term risk, MGRX is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check TXG's competition here
MGRX vs DOCS Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, DOCS has a market cap of 3.8B. Regarding current trading prices, MGRX is priced at $0.36, while DOCS trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas DOCS's P/E ratio is 13.45. In terms of profitability, MGRX's ROE is -1.21%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, MGRX is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check DOCS's competition here
MGRX vs ONEM Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, MGRX is priced at $0.36, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ONEM's P/E ratio is -7.77. In terms of profitability, MGRX's ROE is -1.21%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, MGRX is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check ONEM's competition here
MGRX vs PRVA Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, PRVA has a market cap of 3.2B. Regarding current trading prices, MGRX is priced at $0.36, while PRVA trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas PRVA's P/E ratio is 159.69. In terms of profitability, MGRX's ROE is -1.21%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, MGRX is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check PRVA's competition here
MGRX vs HTFL Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, HTFL has a market cap of 3B. Regarding current trading prices, MGRX is priced at $0.36, while HTFL trades at $29.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas HTFL's P/E ratio is -17.34. In terms of profitability, MGRX's ROE is -1.21%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, MGRX is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check HTFL's competition here
MGRX vs PINC Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, MGRX is priced at $0.36, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas PINC's P/E ratio is 166.24. In terms of profitability, MGRX's ROE is -1.21%, compared to PINC's ROE of -0.02%. Regarding short-term risk, MGRX is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check PINC's competition here
MGRX vs PGNY Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, PGNY has a market cap of 2.3B. Regarding current trading prices, MGRX is priced at $0.36, while PGNY trades at $28.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas PGNY's P/E ratio is 21.07. In terms of profitability, MGRX's ROE is -1.21%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, MGRX is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check PGNY's competition here
MGRX vs WGSWW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, WGSWW has a market cap of 2.1B. Regarding current trading prices, MGRX is priced at $0.36, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas WGSWW's P/E ratio is -0.10. In terms of profitability, MGRX's ROE is -1.21%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, MGRX is more volatile compared to WGSWW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check WGSWW's competition here
MGRX vs WGS Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, MGRX is priced at $0.36, while WGS trades at $67.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas WGS's P/E ratio is 81.32. In terms of profitability, MGRX's ROE is -1.21%, compared to WGS's ROE of -0.28%. Regarding short-term risk, MGRX is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check WGS's competition here
MGRX vs NXGN Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, MGRX is priced at $0.36, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas NXGN's P/E ratio is -266.00. In terms of profitability, MGRX's ROE is -1.21%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, MGRX is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check NXGN's competition here
MGRX vs TDOC Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, TDOC has a market cap of 1.6B. Regarding current trading prices, MGRX is priced at $0.36, while TDOC trades at $8.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas TDOC's P/E ratio is -9.64. In terms of profitability, MGRX's ROE is -1.21%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, MGRX is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check TDOC's competition here
MGRX vs AGTI Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, MGRX is priced at $0.36, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas AGTI's P/E ratio is -71.79. In terms of profitability, MGRX's ROE is -1.21%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, MGRX is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check AGTI's competition here
MGRX vs OMDA Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, OMDA has a market cap of 1.3B. Regarding current trading prices, MGRX is priced at $0.36, while OMDA trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas OMDA's P/E ratio is 309.57. In terms of profitability, MGRX's ROE is -1.21%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, MGRX is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check OMDA's competition here
MGRX vs NUTX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, NUTX has a market cap of 997.9M. Regarding current trading prices, MGRX is priced at $0.36, while NUTX trades at $168.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas NUTX's P/E ratio is 12.95. In terms of profitability, MGRX's ROE is -1.21%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, MGRX is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check NUTX's competition here
MGRX vs CERT Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CERT has a market cap of 989.4M. Regarding current trading prices, MGRX is priced at $0.36, while CERT trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CERT's P/E ratio is 16.31. In terms of profitability, MGRX's ROE is -1.21%, compared to CERT's ROE of -0.01%. Regarding short-term risk, MGRX is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check CERT's competition here
MGRX vs GDRX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, GDRX has a market cap of 987.9M. Regarding current trading prices, MGRX is priced at $0.36, while GDRX trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas GDRX's P/E ratio is 8.64. In terms of profitability, MGRX's ROE is -1.21%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, MGRX is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check GDRX's competition here
MGRX vs CCLDO Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, MGRX is priced at $0.36, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CCLDO's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CCLDO's competition here
MGRX vs HSTM Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, HSTM has a market cap of 792.6M. Regarding current trading prices, MGRX is priced at $0.36, while HSTM trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas HSTM's P/E ratio is 35.70. In terms of profitability, MGRX's ROE is -1.21%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, MGRX is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check HSTM's competition here
MGRX vs EVH Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, EVH has a market cap of 648.5M. Regarding current trading prices, MGRX is priced at $0.36, while EVH trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas EVH's P/E ratio is 576.50. In terms of profitability, MGRX's ROE is -1.21%, compared to EVH's ROE of -0.78%. Regarding short-term risk, MGRX is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check EVH's competition here
MGRX vs PHR Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, PHR has a market cap of 634.2M. Regarding current trading prices, MGRX is priced at $0.36, while PHR trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas PHR's P/E ratio is 36.64. In terms of profitability, MGRX's ROE is -1.21%, compared to PHR's ROE of +0.03%. Regarding short-term risk, MGRX is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check PHR's competition here
MGRX vs MPLN-WT Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, MGRX is priced at $0.36, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, MGRX is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check MPLN-WT's competition here
MGRX vs CTEV Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CTEV has a market cap of 576.9M. Regarding current trading prices, MGRX is priced at $0.36, while CTEV trades at $34.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CTEV's P/E ratio is -2.60. In terms of profitability, MGRX's ROE is -1.21%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, MGRX is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CTEV's competition here
MGRX vs ACCD Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, MGRX is priced at $0.36, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ACCD's P/E ratio is -3.08. In terms of profitability, MGRX's ROE is -1.21%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, MGRX is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check ACCD's competition here
MGRX vs CCLDP Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, MGRX is priced at $0.36, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CCLDP's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CCLDP's competition here
MGRX vs SHCR Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, MGRX is priced at $0.36, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SHCR's P/E ratio is -3.76. In terms of profitability, MGRX's ROE is -1.21%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, MGRX is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SHCR's competition here
MGRX vs NRC Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, NRC has a market cap of 487.7M. Regarding current trading prices, MGRX is priced at $0.36, while NRC trades at $21.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas NRC's P/E ratio is 24.59. In terms of profitability, MGRX's ROE is -1.21%, compared to NRC's ROE of +0.57%. Regarding short-term risk, MGRX is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check NRC's competition here
MGRX vs SOPH Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SOPH has a market cap of 411.1M. Regarding current trading prices, MGRX is priced at $0.36, while SOPH trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SOPH's P/E ratio is -11.50. In terms of profitability, MGRX's ROE is -1.21%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, MGRX is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check SOPH's competition here
MGRX vs SLGCW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, MGRX is priced at $0.36, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, MGRX's ROE is -1.21%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, MGRX is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check SLGCW's competition here
MGRX vs SLGC Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, MGRX is priced at $0.36, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SLGC's P/E ratio is -3.04. In terms of profitability, MGRX's ROE is -1.21%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, MGRX is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check SLGC's competition here
MGRX vs TBRG Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, TBRG has a market cap of 392.7M. Regarding current trading prices, MGRX is priced at $0.36, while TBRG trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas TBRG's P/E ratio is 9.35. In terms of profitability, MGRX's ROE is -1.21%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, MGRX is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check TBRG's competition here
MGRX vs MPLN Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, MGRX is priced at $0.36, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas MPLN's P/E ratio is -0.23. In terms of profitability, MGRX's ROE is -1.21%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, MGRX is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check MPLN's competition here
MGRX vs SLP Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SLP has a market cap of 371.4M. Regarding current trading prices, MGRX is priced at $0.36, while SLP trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SLP's P/E ratio is 17.84. In terms of profitability, MGRX's ROE is -1.21%, compared to SLP's ROE of -0.49%. Regarding short-term risk, MGRX is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SLP's competition here
MGRX vs TRHC Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, MGRX is priced at $0.36, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas TRHC's P/E ratio is -4.27. In terms of profitability, MGRX's ROE is -1.21%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, MGRX is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check TRHC's competition here
MGRX vs SMFR Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, MGRX is priced at $0.36, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SMFR's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, MGRX is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check SMFR's competition here
MGRX vs SPOK Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SPOK has a market cap of 218.3M. Regarding current trading prices, MGRX is priced at $0.36, while SPOK trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SPOK's P/E ratio is 17.42. In terms of profitability, MGRX's ROE is -1.21%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, MGRX is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SPOK's competition here
MGRX vs SY Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SY has a market cap of 188.9M. Regarding current trading prices, MGRX is priced at $0.36, while SY trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SY's P/E ratio is -4.36. In terms of profitability, MGRX's ROE is -1.21%, compared to SY's ROE of -0.16%. Regarding short-term risk, MGRX is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check SY's competition here
MGRX vs AMWL Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, AMWL has a market cap of 155.8M. Regarding current trading prices, MGRX is priced at $0.36, while AMWL trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas AMWL's P/E ratio is -1.80. In terms of profitability, MGRX's ROE is -1.21%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, MGRX is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check AMWL's competition here
MGRX vs HCAT Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, HCAT has a market cap of 144.8M. Regarding current trading prices, MGRX is priced at $0.36, while HCAT trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas HCAT's P/E ratio is 9.80. In terms of profitability, MGRX's ROE is -1.21%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, MGRX is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check HCAT's competition here
MGRX vs CPSI Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, MGRX is priced at $0.36, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CPSI's P/E ratio is -183.80. In terms of profitability, MGRX's ROE is -1.21%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, MGRX is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check CPSI's competition here
MGRX vs AUGX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, MGRX is priced at $0.36, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas AUGX's P/E ratio is -4.99. In terms of profitability, MGRX's ROE is -1.21%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, MGRX is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check AUGX's competition here
MGRX vs OPRX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, OPRX has a market cap of 101.9M. Regarding current trading prices, MGRX is priced at $0.36, while OPRX trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas OPRX's P/E ratio is 4.98. In terms of profitability, MGRX's ROE is -1.21%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, MGRX is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check OPRX's competition here
MGRX vs CCLD Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CCLD has a market cap of 91.8M. Regarding current trading prices, MGRX is priced at $0.36, while CCLD trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CCLD's P/E ratio is 6.55. In terms of profitability, MGRX's ROE is -1.21%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CCLD's competition here
MGRX vs DH Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, DH has a market cap of 75.8M. Regarding current trading prices, MGRX is priced at $0.36, while DH trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas DH's P/E ratio is 2.76. In terms of profitability, MGRX's ROE is -1.21%, compared to DH's ROE of -0.67%. Regarding short-term risk, MGRX is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check DH's competition here
MGRX vs FORA Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, MGRX is priced at $0.36, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas FORA's P/E ratio is -24.11. In terms of profitability, MGRX's ROE is -1.21%, compared to FORA's ROE of -0.17%. Regarding short-term risk, MGRX is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check FORA's competition here
MGRX vs ONMD Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ONMD has a market cap of 38.7M. Regarding current trading prices, MGRX is priced at $0.36, while ONMD trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ONMD's P/E ratio is -4.74. In terms of profitability, MGRX's ROE is -1.21%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, MGRX is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check ONMD's competition here
MGRX vs SNCE Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, MGRX is priced at $0.36, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SNCE's P/E ratio is -0.27. In terms of profitability, MGRX's ROE is -1.21%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, MGRX is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SNCE's competition here
MGRX vs AKLI Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, MGRX is priced at $0.36, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas AKLI's P/E ratio is -0.71. In terms of profitability, MGRX's ROE is -1.21%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, MGRX is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check AKLI's competition here
MGRX vs SHLT Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, MGRX is priced at $0.36, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SHLT's P/E ratio is -3.87. In terms of profitability, MGRX's ROE is -1.21%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, MGRX is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SHLT's competition here
MGRX vs SHCRW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, MGRX is priced at $0.36, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.21%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, MGRX is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SHCRW's competition here
MGRX vs ONMDW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ONMDW has a market cap of 30.9M. Regarding current trading prices, MGRX is priced at $0.36, while ONMDW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ONMDW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, MGRX is more volatile compared to ONMDW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check ONMDW's competition here
MGRX vs EUDA Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, EUDA has a market cap of 27.1M. Regarding current trading prices, MGRX is priced at $0.36, while EUDA trades at $14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas EUDA's P/E ratio is -2.66. In terms of profitability, MGRX's ROE is -1.21%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, MGRX is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check EUDA's competition here
MGRX vs STRM Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, MGRX is priced at $0.36, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas STRM's P/E ratio is -2.40. In terms of profitability, MGRX's ROE is -1.21%, compared to STRM's ROE of -0.32%. Regarding short-term risk, MGRX is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check STRM's competition here
MGRX vs RNLX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, MGRX is priced at $0.36, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas RNLX's P/E ratio is -0.33. In terms of profitability, MGRX's ROE is -1.21%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, MGRX is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check RNLX's competition here
MGRX vs LIFW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, MGRX is priced at $0.36, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas LIFW's P/E ratio is -0.02. In terms of profitability, MGRX's ROE is -1.21%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, MGRX is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check LIFW's competition here
MGRX vs BEATW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, BEATW has a market cap of 19M. Regarding current trading prices, MGRX is priced at $0.36, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas BEATW's P/E ratio is -0.05. In terms of profitability, MGRX's ROE is -1.21%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, MGRX is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check BEATW's competition here
MGRX vs BBLN Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, MGRX is priced at $0.36, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas BBLN's P/E ratio is -0.04. In terms of profitability, MGRX's ROE is -1.21%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, MGRX is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check BBLN's competition here
MGRX vs ETAO Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, MGRX is priced at $0.36, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ETAO's P/E ratio is -0.01. In terms of profitability, MGRX's ROE is -1.21%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, MGRX is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check ETAO's competition here
MGRX vs BFRG Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, BFRG has a market cap of 8M. Regarding current trading prices, MGRX is priced at $0.36, while BFRG trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas BFRG's P/E ratio is -1.26. In terms of profitability, MGRX's ROE is -1.21%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, MGRX is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check BFRG's competition here
MGRX vs HLTH Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, MGRX is priced at $0.36, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas HLTH's P/E ratio is -0.02. In terms of profitability, MGRX's ROE is -1.21%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, MGRX is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check HLTH's competition here
MGRX vs SCNX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, SCNX has a market cap of 5.5M. Regarding current trading prices, MGRX is priced at $0.36, while SCNX trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas SCNX's P/E ratio is -0.14. In terms of profitability, MGRX's ROE is -1.21%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, MGRX is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check SCNX's competition here
MGRX vs UPH Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, MGRX is priced at $0.36, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas UPH's P/E ratio is -0.07. In terms of profitability, MGRX's ROE is -1.21%, compared to UPH's ROE of -1.05%. Regarding short-term risk, MGRX is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check UPH's competition here
MGRX vs UPH-WT Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, MGRX is priced at $0.36, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, MGRX is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check UPH-WT's competition here
MGRX vs PEARW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, MGRX is priced at $0.36, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas PEARW's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.21%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, MGRX is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check PEARW's competition here
MGRX vs PEAR Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, MGRX is priced at $0.36, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas PEAR's P/E ratio is -0.08. In terms of profitability, MGRX's ROE is -1.21%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, MGRX is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check PEAR's competition here
MGRX vs OTRK Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, MGRX is priced at $0.36, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas OTRK's P/E ratio is -0.02. In terms of profitability, MGRX's ROE is -1.21%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, MGRX is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check OTRK's competition here
MGRX vs HCTI Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, HCTI has a market cap of 2.2M. Regarding current trading prices, MGRX is priced at $0.36, while HCTI trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas HCTI's P/E ratio is -0.02. In terms of profitability, MGRX's ROE is -1.21%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, MGRX is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check HCTI's competition here
MGRX vs VSEEW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, VSEEW has a market cap of 1.9M. Regarding current trading prices, MGRX is priced at $0.36, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas VSEEW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, MGRX is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check VSEEW's competition here
MGRX vs VSEE Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, VSEE has a market cap of 1.9M. Regarding current trading prices, MGRX is priced at $0.36, while VSEE trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas VSEE's P/E ratio is -0.22. In terms of profitability, MGRX's ROE is -1.21%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, MGRX is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check VSEE's competition here
MGRX vs CMAX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, MGRX is priced at $0.36, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CMAX's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.21%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, MGRX is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CMAX's competition here
MGRX vs ACON Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ACON has a market cap of 1.5M. Regarding current trading prices, MGRX is priced at $0.36, while ACON trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ACON's P/E ratio is -0.27. In terms of profitability, MGRX's ROE is -1.21%, compared to ACON's ROE of -0.54%. Regarding short-term risk, MGRX is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check ACON's competition here
MGRX vs BFRGW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, BFRGW has a market cap of 1.5M. Regarding current trading prices, MGRX is priced at $0.36, while BFRGW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas BFRGW's P/E ratio is -1.00. In terms of profitability, MGRX's ROE is -1.21%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, MGRX is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check BFRGW's competition here
MGRX vs LIFWZ Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, MGRX is priced at $0.36, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, MGRX is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check LIFWZ's competition here
MGRX vs EUDAW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, EUDAW has a market cap of 1.1M. Regarding current trading prices, MGRX is priced at $0.36, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas EUDAW's P/E ratio is 0.04. In terms of profitability, MGRX's ROE is -1.21%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, MGRX is more volatile compared to EUDAW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check EUDAW's competition here
MGRX vs MSPRZ Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, MGRX is priced at $0.36, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, MGRX is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check MSPRZ's competition here
MGRX vs WORX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, MGRX is priced at $0.36, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas WORX's P/E ratio is -1.17. In terms of profitability, MGRX's ROE is -1.21%, compared to WORX's ROE of -0.65%. Regarding short-term risk, MGRX is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check WORX's competition here
MGRX vs KERNW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, MGRX is priced at $0.36, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas KERNW's P/E ratio is -0.00. In terms of profitability, MGRX's ROE is -1.21%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, MGRX is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check KERNW's competition here
MGRX vs KERN Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, MGRX is priced at $0.36, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas KERN's P/E ratio is -0.01. In terms of profitability, MGRX's ROE is -1.21%, compared to KERN's ROE of -0.17%. Regarding short-term risk, MGRX is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check KERN's competition here
MGRX vs LIFWW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, MGRX is priced at $0.36, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas LIFWW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, MGRX is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check LIFWW's competition here
MGRX vs ZCMD Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ZCMD has a market cap of 41.3K. Regarding current trading prices, MGRX is priced at $0.36, while ZCMD trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ZCMD's P/E ratio is -0.02. In terms of profitability, MGRX's ROE is -1.21%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, MGRX is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check ZCMD's competition here
MGRX vs CMAXW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, MGRX is priced at $0.36, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CMAXW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, MGRX is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CMAXW's competition here
MGRX vs ACONW Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, ACONW has a market cap of 14.9K. Regarding current trading prices, MGRX is priced at $0.36, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas ACONW's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, MGRX is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check ACONW's competition here
MGRX vs MTBCP Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas MTBCP's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, MGRX is more volatile compared to MTBCP. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check MTBCP's competition here
MGRX vs NAVA Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas NAVA's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, Volatility data is not available for a full comparison. MGRX has daily volatility of 6.29 and NAVA has daily volatility of N/A.Check NAVA's competition here
MGRX vs AFFX Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas AFFX's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, MGRX is more volatile compared to AFFX. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check AFFX's competition here
MGRX vs CHNGU Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CHNGU's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, MGRX is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CHNGU's competition here
MGRX vs MTBC Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas MTBC's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, MGRX is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check MTBC's competition here
MGRX vs CHNG Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CHNG's P/E ratio is -152.72. In terms of profitability, MGRX's ROE is -1.21%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, MGRX is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CHNG's competition here
MGRX vs CNVY Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas CNVY's P/E ratio is -71.50. In terms of profitability, MGRX's ROE is -1.21%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, MGRX is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for MGRX.Check CNVY's competition here
MGRX vs KURIU Comparison July 2026
MGRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGRX stands at 3.7M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, MGRX is priced at $0.36, while KURIU trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGRX currently has a P/E ratio of -0.27, whereas KURIU's P/E ratio is N/A. In terms of profitability, MGRX's ROE is -1.21%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, MGRX is less volatile compared to KURIU. This indicates potentially lower risk in terms of short-term price fluctuations for MGRX.Check KURIU's competition here